Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Holmium-166 transarterial radioembolization (TARE) for patients with locally advanced hepatocellular carcinoma (HCC), which is a common type of liver cancer. The goal is to see how effective and safe this treatment is for people whose cancer cannot be removed with surgery. TARE works by delivering tiny radioactive particles directly to the tumor in the liver, which helps to target the cancer while protecting healthy tissue. Researchers will study patients who have received this treatment from January 2010 to December 2024 to learn more about how well it works and what side effects it may cause.

To participate in this trial, patients need to be at least 18 years old and diagnosed with locally advanced HCC that hasn't spread to other parts of the body. They must also meet specific health criteria, such as having a certain level of liver function and being eligible for this targeted treatment after evaluation by a medical team. Participants can expect to undergo regular follow-ups to assess their response to the treatment and overall health. This study aims to provide important insights that could help improve treatment options and survival rates for patients facing this challenging illness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged 18 year or older
• • diagnosed with locally advanced HCC without extra-hepatic metastases
• • HCC must not be amendable to treatment by surgical resection or percutaneous radiofrequency ablation
• • after assessment by the investigator and multidisciplinary tumor board, the patient is considered suitable for protocol treatment with Holmium-166 TARE
• • ECOG performance status 0-2
• • child-Pugh A-B
• • tumor response evaluable with mRECIST criteria during follow-up
• Exclusion Criteria:
• • prior treatment with any of the following treatment modalities for HCC: systemic therapy, hepatic radiation therapy
• • currently enrolled in clinical studies where patient receive investigational therapeutic drug
• • metastatic disease
• • concurrent malignancy
• • active contra-indications to angiography or selective catherization (i.e. severe vascular disease or bleeding diathesis)
• • uncontrolled and/or severe comorbidities (active infection, heart failure,...) with limited estimated life expectancy
• • history of or know allergic reactions to used compounds